

BIOCON GROUP

FACT SHEET

June 2011

Q1 FY 2012 vs. Q1 FY 2011

BIOCON LIMITED (CONSOLIDATED) UNAUDITED		
BALANCE SHEET		<i>(Rs. Crores)</i>
	June-11	March-11
<u>SOURCES OF FUNDS</u>		
Share Capital	100	100
Reserves & Surplus	2,019	1,939
Total Shareholder's Funds	2,119	2,039
Deferred Tax Liability	45	50
Secured Loans	145	204
Unsecured Loans	113	118
Total Loan Funds	258	322
TOTAL	2,422	2,411
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	1,436	1,349
Intangible Assets	224	229
Investments - Liquid Funds	379	400
Investments - Others	62	61
Inventories	309	291
Sundry debtors	444	489
Cash and bank balances	426	403
Loans and advances	157	122
Total Current Assets	1,336	1,305
Less: Current liabilities	1,015	989
Net Current assets	321	316
Net Assets - AxiCorp	-	56
TOTAL	2,422	2,411

**BIOCON LIMITED (CONSOLIDATED) UNAUDITED
PROFIT & LOSS STATEMENT** (Rs. Crores)

Particulars	Q1 FY 12	Q1 FY 11	Variance
<u>INCOME</u>			
Biopharmaceuticals	354	329	8%
Contract research	88	72	22%
Total Sales	442	401	10%
Other income	12	8	
Total Income / Revenues	454	409	11%
<u>EXPENDITURE</u>			
Material & Power Costs	214	192	11%
Staff costs	64	51	27%
Research & Development	20	21	-4%
Other Expenses	23	27	-14%
Manufacturing, staff & other expenses	321	291	10%
PBDIT /EBITDA	133	118	12%
Interest and finance charges	6	7	-13%
Depreciation & Amortisation	45	36	24%
PBT	82	75	9%
Taxes	12	10	19%
NET PROFIT (PAT) WITHOUT AXICORP	70	65	7%
Profit from discontinued (AxiCorp) Operations, net	-	12	
NET PROFIT FOR THE PERIOD	70	77	-9%
EPS Rs.	3.5	3.8	

Note: The figures are rounded off to nearest crores, percentages are based on absolute numbers

Biopharmaceuticals Income includes Licensing development fees of Rs 14 crores in Q1 FY 2012 vs. Licensing Income of Rs.21 crores in Q1 FY 2011.